<DOC>
	<DOCNO>NCT01210664</DOCNO>
	<brief_summary>The investigational therapy study trial , regulatory T cell ( Tregs ) , offer hope stabilize destruction insulin produce beta cell type 1 diabetes . Tregs specialize subset T cell function control immune response . Pre-clinical study non-obese diabetic mouse demonstrate adoptive transfer Tregs slow diabetes progression , case , reverse new onset diabetes . The primary purpose Phase 1 study ass safety feasibility intravenous infusion ex vivo select expand autologous polyclonal Tregs patient type 1 diabetes ( T1DM ) support dose selection future efficacy trial . The study also aim assess effect Tregs beta cell function well measure diabetes severity autoimmune response underlie T1DM .</brief_summary>
	<brief_title>T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs</brief_title>
	<detailed_description>Currently , approve medical treatment preservation body 's ability produce insulin patient Type 1 Diabetes Mellitus ( T1DM ) , progression disease devastate consequence . Inadequate blood glucose control result many long term complication include kidney disease , blindness , amputation nerve damage . In spite advance insulin therapy subsequent glucose control , patient require infuse insulin subcutaneously daily throughout life , monitor diet blood sugar level , deal life-long uncertainty . The investigational therapy study trial , regulatory T cell ( Tregs ) , offer hope stabilize diabetes . Tregs specialize subset T cell function control immune response . Pre-clinical study non-obese diabetic mouse demonstrate adoptive transfer Tregs slow diabetes progression , case , reverse new onset diabetes . The primary objective study ass safety single intravenous infusion Tregs patient T1DM . The study also assess effect Tregs insulin-producing beta cell function well outcomes relate diabetes management . Researchers isolate Tregs patient 's blood use specific T cell surface marker ( CD4 , CD25 , CD127 ) . This subset cell expand laboratory co-stimulating anti-CD3 anti-CD28 immobilize magnetic bead , use growth medium contain human serum IL-2 . Following 14-day expansion , anti-CD3/anti-CD28 bead remove Tregs concentrate consolidated . The cell resuspend sterile infusion solution require concentration infuse back patient standard peripheral intravenous line . Subjects observe overnight clinical research center possible side effect follow infusion . A total 14 subject enrol . The study involve 4 dose cohort 3 4 adult cohort . Each cohort receive increase amount Tregs . Subjects follow five year assess safety Treg therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Diagnosis T1DM within &gt; 3 &lt; 24 month screen accord American Diabetes Association criterion Between 18 45 year age Positive test EpsteinBarr antibody Positive test least one follow antibody : ICA512antibody ICA GAD65antibody Insulin ( assess within 10 day onset insulin therapy ) ZnT8 Peak Cpeptide &gt; 0.1 pmol/ml ( &gt; 0.3 ng/ml ) MMTT challenge Adequate venous access support draw 400 ml whole blood infusion investigational therapy Hemoglobin &lt; 10.0 g/dL ; leukocytes &lt; 3,000/µL ; neutrophil &lt; 1,500/µL ; lymphocyte &lt; 800/µL ; platelet &lt; 100,000/µL Regulatory T cell present peripheral blood &lt; 10 per µl determine flow cytometry Serologic evidence HIV1 HIV2 infection Evidence current hepatitis B demonstrate HBsAg circulate hepatitis B genomes Serologic evidence hepatitis C infection Detectable circulate EBV CMV genome active infection Positive PPD skin test define great equal 10 mm induration Chronic use systemic glucocorticoid immunosuppressive agent , biologic immunomodulators within 6 month prior study entry . Specifically , subject receive 7 day treatment 7.5mg prednisone ( equivalent ) within 6 month prior study entry exclude . History malignancy ( include squamous cell carcinoma skin cervix ) except adequately treat basal cell carcinoma Any chronic illness prior treatment opinion investigator preclude participation trial Pregnant breastfeeding woman , female unwilling use reliable effective form contraception 2 year afer Treg dose male unwilling use reliable effective form contraception 3 month Treg dosing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Treg</keyword>
</DOC>